A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Main Inclusion Criteria:

1. Voluntarily sign the informed consent form.

2. Seasonal allergic rhinitis has been prevalent for at least 2 years.

3. Poor control of seasonal allergic rhinitis with nasal glucocorticoids or othertherapeutic agents during the same pollen season in the past.

4. Positive SPT or serum-specific IgE test results.

5. Symptom severity scores for the season met the enrollment criteria.

Main Exclusion Criteria:

1. Other nasal comorbidities or co-morbidities/states that may be present at the timeof screening that affect efficacy determination.

2. Subjects whose allergen exposures in their home or work environments may be expectedto change significantly during the trial period.

3. Subjects with poorly controlled recent asthma conditions.

4. Presence of current or past history of infection of special concern, e.g., activetuberculosis, helminthic infections, severe herpes virus infections, etc.

5. Previous use of anti-interleukin 4 receptor alpha subunit (IL4Rα) monoclonalantibody.

6. Have a serious underlying medical condition that, in the opinion of theinvestigator, may pose a risk to subject safety by participation in a clinicaltrial.